Logos Global Management LP recently announced the acquisition of new stake in Gracell Biotechnologies Inc ADR (NASDAQ:GRCL). The institutional investor has increased its shareholding in the Healthcare company by 40.28% to 2.52 million shares with purchase of 0.72 million shares. This fresh investment now brings its stake to 2.63% valued currently at $12.3 million. In addition, Sio Capital Management LLC raised its holdings by 2.08 million to 2.08 million shares.
With over 16.0 million Gracell Biotechnologies Inc ADR (GRCL) shares trading Tuesday and a closing price of $9.92 on the day, the dollar volume was approximately $158.74 million. The shares have shown a positive half year performance of 143.73% and its price on 12/26/23 gained nearly 60.26%. Currently, there are 95.93M common shares owned by the public and among those 71.32M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The top 3 mutual fund holders in Gracell Biotechnologies Inc ADR are Biotech Growth Trust Plc, iShares Biotechnology ETF, and BlackRock Event Driven Equity Fun. Biotech Growth Trust Plc owns 0.76 million shares of the company’s stock, all valued at over $3.68 million. iShares Biotechnology ETF sold 2076.0 shares to see its total holdings shrink to 0.37 million shares valued at over $1.82 million and representing 0.39% of the shares outstanding. BlackRock Event Driven Equity Fun now owns shares totaling to 0.07% of the shares outstanding.
Shares of Gracell Biotechnologies Inc ADR (NASDAQ: GRCL) opened at $9.91, up $3.72 from a prior closing price of $6.19. However, the script later moved the day high at 9.95, up 60.26%. The company’s stock has a 5-day price change of 75.58% and 236.27% over the past three months. GRCL shares are trading 331.30% year to date (YTD), with the 12-month market performance up to 342.86% higher. It has a 12-month low price of $1.40 and touched a high of $6.99 over the same period. GRCL has an average intraday trading volume of 554.91K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 85.35%, 123.47%, and 191.34% respectively.
Institutional ownership of Gracell Biotechnologies Inc ADR (NASDAQ: GRCL) shares accounts for 33.21% of the company’s 95.93M shares outstanding. Mutual fund holders own 1.52%, while other institutional holders and individual stakeholders account for 23.01% and — respectively.
It has a market capitalization of $951.63M and a beta (3y monthly) value of -0.67. The earnings-per-share (ttm) stands at -$1.02. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.46% over the week and 10.87% over the month.
Analysts forecast that Gracell Biotechnologies Inc ADR (GRCL) will achieve an EPS of -$0.14 for the current quarter, -$0.21 for the next quarter and -$0.68 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.19 while analysts give the company a high EPS estimate of -$0.05. Comparatively, EPS for the current quarter was -$0.3 a year ago. Earnings per share for the fiscal year are expected to increase by 20.61%, and 6.84% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate Gracell Biotechnologies Inc ADR (GRCL) as a “Strong Buy” at a consensus score of 1.89. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 4 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”
